A Study to Compare Genetic Variations of IGF-I and IGF-II

A Non-Randomized Controlled Cross-Sectional Study to Compare Genetic Variations of IGF-I and IGF-II in Patients With Moderate to Severe Dementia and Younger Family Members, in Relation to Age-Matched Unaffected Controls

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01329523

Enrollment

Registered

2011-04-06

Start date

2010-11-30

Completion date

2011-10-31

Last updated

2011-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Keywords

Dementia, Insulin-like growth factor, IGF, APO E4, Genetics

Brief summary

The purpose of this study is to determine if insulin-like growth factors (IGF) play a role in the development of dementia, specifically Alzheimer's disease (AD). The study will compare results from genetic testing between patients with AD and two other groups: younger biological family members of the AD patients and individuals without AD matched by age to the AD patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 81 Years

Healthy volunteers

Yes

Inclusion criteria

* Men and women between the ages of 50 and 81 years old who have a diagnosis of dementia * Men and women who are at least 18 years old and are biologically related to the study subject with dementia * Control subjects must not have a diagnosis of dementia and must be matched in age to the study subjects with dementia

Exclusion criteria

* Biological family members of the dementia patient who are either younger than 17 years of age or older than the patient with dementia * Biological family members with a diagnosis of dementia * Age-matched control subjects with a diagnosis of dementia

Design outcomes

Primary

Measure	Time frame	Description
Genetic polymorphisms of insulin-like growth factors	Single clinic visit (day 1)	This study consists of a single clinic visit. After subject has completed the informed consent process and meets eligibility criteria, a blood sample and a saliva sample will be collected. Genetic results from this one-time specimen collection will be evaluated and compared with results from participants in the other two study groups. Outcomes will be measured comparatively.

Secondary

Measure	Time frame	Description
Genetic testing of Apolipoprotein (APO) E4	Single clinic visit (day 1)	This study consists of a single clinic visit. After subject has completed the informed consent process and meets eligibility criteria, a blood sample and a saliva sample will be collected. Genetic results from this one-time specimen collection will be evaluated and compared with results from participants in the other two study groups. Outcomes will be measured comparatively.

Countries

United States

Outcome results